Macroeconomic uncertainties could impact spending in academia and biopharma.
X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...
Zacks.com on MSN4h
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 EarningsFor the quarter ended December 2024, 10x Genomics (TXG) reported revenue of $165.02 million, down 10.3% over the same period last year. EPS came in at -$0.40, compared to -$0.41 in the year-ago ...
Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
生物科技行业面临挑战，10X Genomics Inc (TXG)股价跌至52周新低，触及11.89美元。根据 InvestingPro 数据显示，技术指标表明该股票已处于超卖区域，公司保持着4.9的健康流动比率。这一最新价格水平凸显了公司股价的急剧下跌，过去一年累计下跌75.65%。投资者正在应对行业整体压力和公司特定不利因素的双重影响，导致持续抛售，最终使公司股价创下新低。这个52周低点清晰地 ...
Investing.com -- 实验室工具设备行业的公司股票，包括Bruker、Illumina、Quanterix、Bio-Techne、10X Genomics和Qiagen，在盘前交易中出现下跌。这一下跌趋势是在美国国立卫生研究院（NIH）宣布计划通过降低研究机构向政府收取的最高间接成本率来大幅减少对医学研究人员的报销后出现的。
The Dassault Falcon 10X is a long-range business jet that is being developed by French aircraft manufacturer, Dassault Aviation. It was expected that certification and development will take place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback